While it is not yet known why Nephrogenic Systemic Fibrosis (NSF) has become so much more common in the last eight years, some research has suggested a link between NSF and Gadolinium used in MRIs. One such study, conducted by Dr. T. Grobner from the Department of Nephrology, General Hospital of Wiener Neustadt, Austria noted that five out of nine patients diagnosed with NSF had received an MRI which involved the use of Gadolinium-based dyes as a contrast agent. These dyes were manufactured by GE.
Although the FDA has not yet recalled Gadodiamide for use in products, they have sent out warnings about the use of gadolinium-based contrast agents in patients with kidney disease. They have also created a page about Gadolinium-Containing Contrast agents on which they state: “The FDA is evaluating important safety information about gadolinium-containing contrast agents and a disease known as Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD) that occurs in patients with moderate to severe kidney disease.”
We urge any patient who has received or who is about to receive an MRI to review the information, including PDF files and public health advisories, on the above FDA information page.
If you have any of the symptoms of Nephrogenic Systemic Fibrosis (NSF) we suggest you contact your physician immediately so you can be properly tested and diagnosed. This is a serious illness!
Patients who have developed NSF after receiving an MRI that involved the use of Gadodiamide or Gadolinium-containing contrast agents may obtain more information from this Gadolinium attorney’s page, this Wikipedia entry, and this page by the Food and Drug Administration about Gadolinium caused NSF investigations.